Preserved coronary flow reserve in viable myocardium: Further evidence for the microvascular hypothesis

American Heart Journal

Volumn 141, Issue 3, 2001, Pages 329-330

  Angeja, Brad G ^a   Gibson, C Michael ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOT LYSIS; CELL VIABILITY; CORONARY ARTERY BLOOD FLOW; DOPPLER ECHOCARDIOGRAPHY; EDITORIAL; HEART MUSCLE; HEART MUSCLE PERFUSION; HUMAN; MICROVASCULARIZATION; MORTALITY; PRIORITY JOURNAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0035096911     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2001.113075     Document Type: Article

References (12)

1. Phase I findings: TIMI Study Group
2. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration: Thrombolysis In Myocardial Infarction (TIMI) Study Group
3. Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency"; (outcome in the thrombolysis and angioplasty in myocardial infarction trials): Thrombolysis and Angioplasty in Myocardial Infarction Study Group
4. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction
5. Determinants and prognostic implications of persistent ST-segment elevation after primary angioplasty for acute myocardial infarction: Importance of microvascular reperfusion injury on clinical outcome
6. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs
7. Role of coronary artery lumen enlargement in improving coronary blood flow after balloon angioplasty and stenting: A combined intravascular ultrasound Doppler flow and imaging study
8. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction
9. Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction: The TIMI Study Group. Thrombolysis in myocardial infarction
10. Reduced coronary vasodilator function in infarcted and normal myocardium after myocardial infarction
11. Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial
12. Abciximab improves both epicardial flow and myocardial reperfusion in ST elevation myocardial infarction: A TIMI 14 analysis